230 related articles for article (PubMed ID: 30624089)
1. Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.
Semaan A; Haddad FG; Eid R; Kourie HR; Nemr E
Future Oncol; 2019 Feb; 15(5):533-541. PubMed ID: 30624089
[TBL] [Abstract][Full Text] [Related]
2. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
[TBL] [Abstract][Full Text] [Related]
3. Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.
Chi EA; Schweizer MT
Clin Genitourin Cancer; 2017 Oct; 15(5):e855-e857. PubMed ID: 28465048
[No Abstract] [Full Text] [Related]
4. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N; Einhorn LH; Althouse SK; Ammakkanavar NR; Musapatika D; Albany C; Vaughn D; Hanna NH
Ann Oncol; 2018 Jan; 29(1):209-214. PubMed ID: 29045540
[TBL] [Abstract][Full Text] [Related]
5. Immune mechanisms and possible immune therapy in testicular germ cell tumours.
Chovanec M; Mardiak J; Mego M
Andrology; 2019 Jul; 7(4):479-486. PubMed ID: 31169364
[TBL] [Abstract][Full Text] [Related]
6. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors.
Einhorn LH; Williams SD; Chamness A; Brames MJ; Perkins SM; Abonour R
N Engl J Med; 2007 Jul; 357(4):340-8. PubMed ID: 17652649
[TBL] [Abstract][Full Text] [Related]
7. [Therapy of germ cell tumors. Model for interdisciplinary treatment approach].
Schmoll HJ
Med Klin (Munich); 1996 Apr; 91 Suppl 3():80-4. PubMed ID: 8692125
[No Abstract] [Full Text] [Related]
8. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: the University of Michigan experience and literature review.
Ayash LJ; Clarke M; Silver SM; Braun T; Uberti J; Ratanatharathorn V; Reynolds C; Ferrara J; Broun ER; Adams PT
Bone Marrow Transplant; 2001 May; 27(9):939-47. PubMed ID: 11436104
[TBL] [Abstract][Full Text] [Related]
9. Promising novel therapies for relapsed and refractory testicular germ cell tumors.
Kozakova K; Mego M; Cheng L; Chovanec M
Expert Rev Anticancer Ther; 2021 Jan; 21(1):53-69. PubMed ID: 33138660
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for the salvage treatment of desperate germ cell tumor: A case report.
Aksun MS; Ucgul E; Sahin TK; Guven DC; Aksoy S
J Oncol Pharm Pract; 2021 Sep; 27(6):1516-1519. PubMed ID: 33283628
[TBL] [Abstract][Full Text] [Related]
11. Identification of a subgroup with worse prognosis among patients with poor-risk testicular germ cell tumor.
Kojima T; Kawai K; Tsuchiya K; Abe T; Shinohara N; Tanaka T; Masumori N; Yamada S; Arai Y; Narita S; Tsuchiya N; Habuchi T; Nishiyama H
Int J Urol; 2015 Oct; 22(10):923-7. PubMed ID: 26094715
[TBL] [Abstract][Full Text] [Related]
12. Multi-modality treatment of advanced malignant germ cell tumours in males. I. Experience with cis-platinum-based combination chemotherapy.
Klepp O; Fosså SD; Ous S; Lien H; Stenwig JT; Abeler V; Eliassen G; Høst H
Scand J Urol Nephrol; 1984; 18(1):13-9. PubMed ID: 6201998
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.
Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ
Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648
[TBL] [Abstract][Full Text] [Related]
14. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors.
Yetisyigit T; Babacan N; Urun Y; Seber ES; Cihan S; Arpaci E; Yildirim N; Aksoy S; Budakoglu B; Zengin N; Oksuzoglu B; Yalcin BC; Alkis N
Asian Pac J Cancer Prev; 2014; 15(2):831-5. PubMed ID: 24568504
[TBL] [Abstract][Full Text] [Related]
15. High dose chemotherapy followed by autologous bone marrow re-infusion in relapsing or refractory testicular cancer.
Sleijfer DT; Mulder PO; de Vries EG; Koops HS; Willemse PH; Sibinga CT; Mulder NH
Prog Clin Biol Res; 1988; 269():429-37. PubMed ID: 2839849
[No Abstract] [Full Text] [Related]
16. New Anti-Cancer Strategies in Testicular Germ Cell Tumors.
Chieffi P; De Martino M; Esposito F
Recent Pat Anticancer Drug Discov; 2019; 14(1):53-59. PubMed ID: 30636617
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment of advanced testicular cancer.
Feldman DR; Bosl GJ; Sheinfeld J; Motzer RJ
JAMA; 2008 Feb; 299(6):672-84. PubMed ID: 18270356
[TBL] [Abstract][Full Text] [Related]
19. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
[TBL] [Abstract][Full Text] [Related]
20. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.
Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G;
Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
